CD274 and neoplasm: Mobilizing the tumor microenvironment (TME) is a major therapeutic advancement in cancer, particularly with checkpoint inhibitors which augment the PD-1/PD-L1 signaling pathway to induce a cytotoxic T cell immune response against tumor cells.